Cargando…
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
The first advance in the history of studies on prostate cancer (PCa) and androgens was the development of treatment with castration and administration of estrogen by Charles B. Huggins, who won the Nobel Prize in Physiology and Medicine. Since then, and for 70 years, androgen deprivation therapy has...
Autores principales: | Kosaka, Takeo, Miyajima, Akira, Oya, Mototsugu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165281/ https://www.ncbi.nlm.nih.gov/pubmed/25279351 http://dx.doi.org/10.3389/fonc.2014.00247 |
Ejemplares similares
-
Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013) -
Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014) -
Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2017) -
Anesthesia and Oncology: Friend or Foe?
por: Buddeberg, Bigna S., et al.
Publicado: (2022) -
Editorial: Anesthesia and cancer: Friend or foe?
por: Bezu, Lucillia, et al.
Publicado: (2022)